About The Study: The results of this randomized clinical trial show that adjunctive semaglutide significantly improved glycemic control and weight outcomes in individuals with schizophrenia spectrum disorders. Secondary outcomes were exploratory. These findings support the use of glucagon-like peptide–1 receptor agonists (GLP-1RAs) as a potential early intervention strategy to reduce cardiometabolic risk in this vulnerable population.
Corresponding Author: To contact the corresponding author, Anders Fink-Jensen, DMSci, email anders.fink-jensen@regionh.dk.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(10.1001/jamapsychiatry.2025.3639)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2025.3639?guestAccessKey=a653e030-9988-447d-8e8d-57e394bab5bf&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=120325
Journal
JAMA Psychiatry